Unknown

Dataset Information

0

Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity.


ABSTRACT: The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not achieve the clinical benefits that were predicted in a number of promising preclinical studies. The current availability of several immune modulatory and targeting approaches opens the way to many potential therapeutic combinations. In particular, the evidence that the immune-related effects that are elicited by immunogenic cell death (ICD)-inducing therapies are strictly associated with DC engagement and activation strongly support the combination of ICD-inducing and DC-based immunotherapies. In this review, we examine the data in recent studies employing tumor cells, killed through ICD induction, in the formulation of anticancer DC-based vaccines. In addition, we discuss the opportunity to combine pharmacologic or physical therapeutic approaches that can promote ICD in vivo with in situ DC vaccination.

SUBMITTER: Lamberti MJ 

PROVIDER: S-EPMC7151083 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity.

Lamberti María Julia MJ   Nigro Annunziata A   Mentucci Fátima María FM   Rumie Vittar Natalia Belén NB   Casolaro Vincenzo V   Dal Col Jessica J  

Pharmaceutics 20200312 3


The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer management have been well documented after more than twenty-five years of experimentation, and, by now, undeniably accepted. On the other hand, it is equally evident that DC-based vaccination as monotherapy did not achieve the clinical benefits that were predicted in a number of promising preclinical studies. The current availability of several immune modulatory and targeting approaches opens the way to many potent  ...[more]

Similar Datasets

| S-EPMC11373825 | biostudies-literature
| S-EPMC8102907 | biostudies-literature
| S-EPMC7486645 | biostudies-literature
| S-EPMC2493000 | biostudies-other
2024-12-10 | GSE264513 | GEO
2024-12-11 | GSE283933 | GEO
| S-EPMC10762337 | biostudies-literature
| S-EPMC2742361 | biostudies-literature
| S-EPMC5368353 | biostudies-other
| S-EPMC6726581 | biostudies-literature